Objective-Platelet α 2A -adrenergic receptors (ARs) mediate platelet aggregation in response to sympathetic stimulation. The 6.3-kb variant of α 2A -AR gene is associated with increased epinephrine-induced platelet aggregation in healthy volunteers. The cytochrome P450 2C19*2 (CYP2C19*2) loss-of-function allele influences P2Y12-mediated platelet inhibition and hence the rate of major adverse cardiovascular events. We assessed the influence of 6.3-kb α 2A -AR gene variant on platelet aggregation and its interaction with CYP2C19*2 loss-of-function allele in patients with stable angina on aspirin and clopidogrel (dual antiplatelet therapy). Approach and Results-Aggregation to 5 increasing doses of epinephrine (from 0.156 to 10 μmol/L) was assessed in aggregation units by Multiplate Analyzer and platelet reactivity in P2Y12 reactivity units and % inhibition by VerifyNow P2Y12 assay before percutaneous revascularization. Gene polymorphisms were analyzed with TaqMan Drug Metabolism assay. Of 141 patients, aggregation was higher in 6.3-kb carriers (n=52) when compared with wild types (n=89) at all epinephrine doses (P<0.05) apart from 10 μmol/L (P=0.077). Percentage inhibition was lower (P=0.048) in 6.3-kb α 2A -AR carriers. Percentage inhibition was lower (P=0.005) and P2Y12 reactivity units was higher (P=0.012) in CYP2C19*2 allele carriers. Higher P2Y12 reactivity units (P=0.037) and lower percentage inhibition (P=0.009) were observed in carriers of both 6.3-kb α 2A -AR variant and CYP2C19*2 allele when compared with wild-type or with either mutation on its own.
D espite dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, there is a considerable interindividual variability of ADP-induced, purinergic receptor P2Y12 (P2Y12)-mediated platelet aggregation. The explanation for such wide interindividual variability remains unclear but is felt to be important because suboptimal platelet inhibition in some patients equates to an increased risk of cardiovascular events (ie, patients with insufficient platelet inhibition from the P2Y12 antagonist, clopidogrel, have been shown to have an increased risk of myocardial infarction and stent thrombosis after coronary stent implantation). [1] [2] [3] [4] Although the interindividual variability has been reduced with the introduction of more potent P2Y12 inhibitors, such as prasugrel or ticagrelor, 5, 6 variability continues to exist, 7 suggesting that other signaling pathways or genetic polymorphisms may be important. 8, 9 Variability in platelet response has been partly attributed to the influence of environmental factors, such as smoking, body weight, and alcohol; however, genetic polymorphisms may play a crucial role as well. The cytochrome P450 2C19*2 (CYP2C19*2) loss-of-function allele exemplifies this with its known influence on ADP-induced platelet aggregation. 10 Carriers of this particular variant have been shown to be less responsive to clopidogrel, resulting in suboptimal platelet inhibition and hence an increased rate of cardiovascular events. [11] [12] [13] [14] [15] [16] In the same way that the platelet possesses multiple receptors and signaling pathways important in platelet activation, aggregation, and arterial thrombus development, there are several genetic polymorphisms that influence platelet biology. 17 Information as to whether these genetic polymorphisms act in a synergistic or additive manner remains poorly understood, particularly in patients taking DAPT.
Epinephrine is an important mediator of platelet aggregation, and through the stimulation of α 2A -ARs on the platelet membrane surface 18 plays a crucial role in the pathogenesis of ischemic syndromes. 19 Previous studies suggest that ≈30% of healthy volunteers 20, 21 and patients with stable coronary artery disease taking aspirin and clopidogrel 22 have increased platelet reactivity in response to epinephrine. Furthermore, Yee et al 21 previously demonstrated that healthy volunteers who have the greatest platelet reactivity to epinephrine aggregate more in response to other agonists, such as ADP. Work by Freeman et al 20 in healthy volunteers suggests that this increased platelet reactivity in response to epinephrine may be attributable to a genetic variant of the α 2A -ARs (6.3-kb variant). Therefore, the primary aim was to investigate the functional effect of the 6.3-kb α 2A -AR variant in patients with stable coronary disease taking aspirin and clopidogrel. The secondary aim was to investigate the potential interaction on platelet aggregation between the 6.3-kb α 2A -AR variant and CYP2C19*2 loss-of-function allele.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Genotype and Clinical Characteristics of the Patients
A total of 141 patients were enrolled. The allele and genotype frequencies for both the α 2A -AR and the CYP2C19 polymorphism are reported in Table 1 . The observed frequencies for both polymorphisms were in Hardy-Weinberg equilibrium and similar to that previously reported. 16, 20, 23 The clinical characteristics are summarized in Table 2 . There were no differences between the wild-type group and the patients carrying the α 2A -AR mutation.
Correlation Between VerifyNow and Multiplate Analyzer
There was a significant correlation between P2Y12 reactivity unit (PRU) and ADP-induced aggregation from the Multiplate Analyzer (r=0.59; P<0.0001), as well as a significant negative correlation between percentage inhibition and ADP-induced aggregation (aggregation unit [AU]) from the Multiplate Analyzer (r=-0.63; P<0.0001) in patients taking both aspirin and clopidogrel. There was no significant correlation seen either between PRU and 2.5-μmol/L epinephrine-induced aggregation (r=0.08; P=ns) or percentage inhibition and 2.5-μmol/L epinephrine-induced aggregation (r=-0.13; P=ns) or at any other concentration tested on the Multiplate. However, there was a significant correlation between ADP and epinephrine-induced aggregation using the Multiplate Analyzer (r=0.44; P<0.0001).
Platelet Aggregation Response to Epinephrine
Dose-response aggregation curve to increasing doses of epinephrine is shown in Figure 1 . In wild-type patients, the aggregation response increased to increasing concentrations of epinephrine (from 10±6.3 to 22±12.6 AU; ANOVA, At the multivariable analysis (Table 3) , the presence of the α 2A -AR mutation (carrier status) was the strongest independent predictor of epinephrine-induced aggregation. Likewise, a significant association with epinephrine-induced aggregation was also observed with angiotensin-converting enzyme-inhibitors and β-blockers.
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P2Y12-Mediated Aggregation With 6.3-/6.7-kb α 2A -AR and CYP2C19*2 Polymorphisms
The presence of the 6.3-kb α 2A -AR mutation influenced P2Y12-mediated aggregation (Figure 2A ). Percentage P2Y12-mediated platelet inhibition was significantly lower in 6.3-kb α 2A -AR carriers when compared with the wild types (37.6±26.7% versus 47.6±28.5%; P=0.048), with a trend toward higher PRU values (208±97 versus 179±107 U; P=0.127).
The presence of the CYP2C19*2 loss-of-function allele significantly influenced P2Y12-mediated aggregation ( Figure 2B ). Percentage P2Y12-mediated platelet inhibition was significantly lower in the carrier group when compared with the wild-type group (34±25.8% versus 48.6±28.2%; P=0.005), with significantly higher PRU values (222±94 versus 174±105 U; P=0.012).
Additive Effect of the 6.3-kb α 2A -AR Variant and CYP2C19*2 Allele on P2Y12-Mediated Aggregation
A total of 63/141 (44%) of the study group did not carry either the 6.3-kb α 2A -AR variant or the CYP2C19*2 loss-of-function allele; 32/141 (21%) patients were 6.3-kb α 2A -AR carrier but wild type for CYP2C19 polymorphism; 26/141 (18%) patients were wild type for α 2A -AR polymorphism but were carrier for the CYP2C19*2 loss-of-function allele; finally, 20/141 (14%) patients were carrying both the 6.3-kb α 2A -AR variant and the CYP2C19*2 loss-of-function allele. There was no association between the 2 mutations (P=0.258).
When we explored the effect of each mutation alone and then in combination, we found that carriers of both the 6.3-kb α 2A -AR variant and the CYP2C19*2 loss-of-function allele have an additive effect on P2Y12-mediated platelet aggregation ( Figure 3 ). In the presence of both mutations, a significantly higher level of PRU (P=0.037) and significantly lower percentage P2Y12-mediated platelet inhibition (P=0.009) were observed when compared with wild-type patients or with either mutation on its own.
Discussion
Our study demonstrates that not only genetic polymorphisms of the α 2A -AR are relatively common but also the presence of this polymorphism modulates platelet reactivity in response to epinephrine in patients with stable angina, despite loading with 600 mg of clopidogrel and 500 mg of aspirin. In addition, the 6.3-kb α 2A -AR variant exerts an additive effect with CYP2C19*2 loss-of-function allele further increasing residual platelet reactivity.
Prevalence and Role of α 2A -AR Polymorphism
Epinephrine is a potent mediator of platelet aggregation through the stimulation of α 2A -ARs on the platelet membrane surface. 18 Of note, this receptor presents a relatively common 6.7-/6.3-kb polymorphism able to modulate platelet function that is detectable in approximately one third of healthy volunteers and patients with acute coronary syndromes (ACS). 20, 23 In the current study, we found again that approximately one third of our patients with stable angina was either heterozygous or homozygous for the α 2A -AR polymorphism. 
Influence of DAPT on Epinephrine-Induced Aggregation
Recent work shows that 22, 24 aspirin and clopidogrel can significantly modulate not only ADP but also epinephrine-induced platelet aggregation. The average aggregation response to epinephrine is significantly reduced in patients with coronary artery disease taking both aspirin and clopidogrel when compared with control healthy volunteers naïve to therapy. Notably in patients with coronary artery disease, the response elicited by epinephrine is markedly heterogeneous, and in treated patients a significant interaction was observed in platelet aggregation response to epinephrine and ADP (ie, those patients with increased epinephrine-induced platelet response presented also an increased response to ADP). This interaction is limited to these 2 pathways and not observed with other pathways, such as arachidonic acid, thrombin receptor-activating peptide, and collagen. These data fit with our current observation in that this heterogeneity can be partly attributed to the presence of α 2A -AR polymorphism and to its interaction with CYP2C19*2 allele. The presence of the 6.3-kb α 2A -AR variant was associated with increased responsiveness to epinephrine-induced aggregation in the initial healthy volunteer cohort. 20 In keeping with this study, we found in our patients with stable angina that the presence of the α 2A -AR polymorphism was associated with increased epinephrine-induced aggregation, despite DAPT. At the multivariable analysis, carrying the 6.3-kb α 2A -AR variant was the strongest predictor of the enhanced epinephrine-induced platelet aggregation.
In a previous study, we were unable to detect any major effect of the 6.3-kb α 2A -AR variant on platelet response in patients with non-ST-segment-elevation myocardial infarction ACS treated with DAPT. 23 This apparent discrepancy with the current findings can have different explanations. First, in the non-ST-segment-elevation myocardial infarction ACS study, platelet responsiveness was not evaluated in response to epinephrine but only in the context of ADP-induced aggregation as measured by light transmission aggregation and using the vasodilator-stimulated phosphoprotein phosphorylation assay. Second, lack of interaction between α 2A -AR polymorphism and ADP-induced aggregation could be because of the fact that patients with ACS have higher levels of circulating catecholamines, in general, and epinephrine, in particular. This prolonged or repeated exposure to epinephrine leads to downregulation of ARs. [25] [26] [27] Therefore, patients with ACS may Figure 3 . Platelet reactivity unit (PRU) and percentage P2Y12-mediated platelet inhibition with combined 6.3-/6.7-kb α 2A -adrenergic receptor and CYP2C19*2 polymorphisms. Post-test ANOVA confirmed that the presence of both mutations leads to a significant increase in PRU value (left; *P=0.037) and a significant decrease in percentage inhibition (right; **P=0.009). be less responsive to the effects of catecholamines and other mediators, such as ADP, making it difficult to identify differences. Finally, previous evidence shows that baseline platelet reactivity in patients with ACS is already elevated, so detecting subtle differences in platelet reactivity in response to various agonists may be more difficult. 28, 29 
Clinical Implications
Our study further adds on the available literature showing for the first time that the α 2A -AR polymorphism influences P2Y12-mediated platelet aggregation. More importantly, a clear functional interaction was observed with CYP2C19*2 loss-of-function polymorphism. The CYP2C19*2 allele has been shown to be an important genetic mediator of P2Y12-mediated platelet responses in patients taking clopidogrel, which in turn translates into a higher rate of stent thrombosis and cardiovascular death. [11] [12] [13] [14] [15] [16] This variant seems to have little effect, if any, in patients with ACS taking more potent P2Y12 inhibitors, such as prasugrel or ticagrelor. 5, 6 Yet, recent reports have shown some residual interindividual variability, despite prasugrel that could be because of other signaling pathways or genetic polymorphisms. 8, 9 In this study, we corroborate with previous work that the presence of the CYP2C19*2 loss-of-function allele influences on treatment P2Y12-mediated platelet responses, and provide novel insights that α 2A -AR polymorphism mediates P2Y12-mediated platelet responses in stable coronary artery disease patients taking clopidogrel. Furthermore, in those individuals who carry both mutations, it is notable that there is an additive effect on the P2Y12-mediated platelet responses. This raises the question as to whether this genetic combination could have a clinical effect on major adverse cardiovascular events, and whether this enhanced platelet reactivity would benefit from more potent P2Y12 inhibitors also in patients with stable coronary disease.
Angiotensin-converting enzyme-inhibitors were associated with an increased response to epinephrine on platelet aggregation. This can be explained through the inhibitory modulation exerted by angiotensin-converting enzyme-inhibitors on peripheral adrenergic transmission. 30 We might speculate, on this background of reduced adrenergic stimulation, a hyper-responsiveness of platelet α 2 -ARs to epinephrine. On the contrary, β-blockers were associated with a reduced epinephrine-induced platelet aggregation. This finding confirms the previously described transregulation of the platelet α 2 -adrenergic signal transduction pathway by chronic β-blockade therapy. 31 In this work, in fact, Schwencke et al 31 reported a reduction of the catecholamine-induced platelet activation and aggregation in healthy volunteers under chronic β-blockade.
Limitations
We recognize the limited sample size of our study, and our findings need replication in larger cohort of patients. Although we found an additive effect from the α 2A -AR polymorphism and CYP2C19*2 loss-of-function allele on platelet response, it is likely to be the case that other polymorphisms may have had an additional additive or possibly antagonistic effect on platelet responses; however, these were not measured. As is the case for many studies measuring platelet function, in this study, we have not measured baseline platelet function in treatment-naïve patients. Nevertheless, high on treatment platelet reactivity has been shown to be clinically relevant. [1] [2] [3] [4] Our study lacks clinical follow-up to ascertain the clinical relevance of this additive effect seen using ex vivo platelet function testing. Finally, we cannot exclude that the apparent discrepancy between the current results and our previous study 23 could be partly attributed to the different platelet assays used.
Conclusions
The presence of α 2A -AR polymorphism is associated with increased platelet reactivity in response to epinephrine and seems to have an additive effect along with the CYP2C19*2 loss-of-function allele on P2Y12-mediated platelet responses in patients with chronic stable angina taking DAPT. Additional studies are needed to assess whether carriers of both polymorphisms are exposed to an excessive risk of thrombotic events, especially during adrenergic stress.
